Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 7:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 415 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bone Grafting Clear all
Recruiting No phase listed Observational

Prospective Registry to Evaluate Outcomes of NanoBone® Bone Graft in Acute Trauma

NCT06256458
View directory record Official record
Conditions
Fractures, Bone
Interventions
NanoBone® Bone Graft
Device
Lead sponsor
Artoss Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 6, 2026, 7:35 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Congenital Pseudarthrosis of the Tibia.

NCT07112443
View directory record Official record
Conditions
Congenital Pseudarthrosis of Tibia
Interventions
NVD003, Iliac Crest Bone Graft
Biological · Procedure
Lead sponsor
Novadip Biosciences
Industry
Eligibility
Up to 17 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Phoenix, Arizona • Loma Linda, California • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Sep 6, 2026, 7:35 PM EDT
Terminated Phase 2 Interventional Results available

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

NCT00720629
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Visilizumab, Tacrolimus, Methotrexate, Antithymocyte globulin (ATG)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Sep 6, 2026, 7:35 PM EDT
Completed Phase 2 Interventional Results available

Reduced Intensity Conditioning Using CD3+/CD19+ Depletion for Non Malignant Transplantable Diseases

NCT02277639
View directory record Official record
Conditions
Bone Marrow Failure Syndromes, Immunodeficiencies, Immune Dysregulation Syndromes
Interventions
CliniMACs device
Device
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 22 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Sep 6, 2026, 7:35 PM EDT
Recruiting Not applicable Interventional

Comparison of Two Types of Bone Grafts in Patients Who Need One of Their Front Teeth Removed and Replaced With an Implant

NCT06722482
View directory record Official record
Conditions
Ridge Preservation, Allografts, Extraction, Tooth, Xenograft
Interventions
FDBA, CEBX
Device
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Sep 6, 2026, 7:35 PM EDT
Recruiting Not applicable Interventional

QL vs LAI for Palatoplasty

NCT06420336
View directory record Official record
Conditions
Post-operative Pain, Opioid Use, Cleft Palate
Interventions
Quadratus lumborum block, Local anesthetic infiltration
Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
6 Years to 18 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 6, 2026, 7:35 PM EDT
Terminated No phase listed Observational

Localized Alveolar Ridge Augmentation With Dental Implant

NCT00991965
View directory record Official record
Conditions
Alveolar Bone Loss
Interventions
INFUSE® Bone Graft
Device
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
6
States / cities
Loma Linda, California • Los Angeles, California • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Sep 6, 2026, 7:35 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer

NCT02999854
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions
ATIR101, Cyclophosphamide, T-cell depleted HSCT from a related, haploidentical donor, T-cell replete HSCT from a related, haploidentical donor
Biological · Drug · Procedure
Lead sponsor
Kiadis Pharma
Industry
Eligibility
18 Years to 70 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
12
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Sep 6, 2026, 7:35 PM EDT
Completed Not applicable Interventional Results available

Augment® Injectable Bone Graft Compared to Autologous Bone Graft as a Bone Regeneration Device in Hindfoot Fusions

NCT01305356
View directory record Official record
Conditions
Degenerative Joint Disease, Congenital Deformity, Arthritis, Osteoarthritis, Rheumatoid Arthritis
Interventions
Augment® Injectable Bone Graft, Autologous bone graft
Device · Procedure
Lead sponsor
BioMimetic Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
20
States / cities
Tucson, Arizona • San Francisco, California • Glenview, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2018 · Synced Sep 6, 2026, 7:35 PM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Wound Healing Following Extraction and Ridge Preservation in Smokers and Non-smokers

NCT07372183
View directory record Official record
Conditions
Smoking, Cigarette, Alveolar Bone Grafting, Wound Healing, Bone Healing, Tooth Extraction Site Healing
Interventions
observational study
Other
Lead sponsor
Marquette University
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 6, 2026, 7:35 PM EDT
Completed Phase 2 Interventional

Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer

NCT00003335
View directory record Official record
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclosporine, melphalan, methylprednisolone, umbilical cord blood transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 54 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Sep 6, 2026, 7:35 PM EDT
Completed Phase 3 Interventional Results available

Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder

NCT00755040
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
cyclosporine ophthalmic emulsion, placebo
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
5
States / cities
Palo Alto, California • Chicago, Illinois • Nashville, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 6, 2026, 7:35 PM EDT
Completed Phase 2 Interventional Results available

Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies

NCT02120157
View directory record Official record
Conditions
Myeloablative Conditioning, HLA-mismatched Bone Marrow Transplantation, Graft Survival, Transplantation, Bone Marrow
Interventions
Cyclophosphamide, TBI, Busulfan, Unmanipulated Bone Marrow, Tacrolimus, Mycophenolate mofetil
Drug · Radiation · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
6 Months to 25 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
7
States / cities
Aurora, Colorado • Wilmington, Delaware • St. Petersburg, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2021 · Synced Sep 6, 2026, 7:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Long Term Outcomes Follow-up of Glenoid Anchor Peg Component Fixation

NCT02983357
View directory record Official record
Conditions
Arthritis
Interventions
CT, X-Ray, Physical assessment, Questionnaire
Radiation · Other
Lead sponsor
University of Nebraska
Other
Eligibility
44 Years to 94 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 6, 2026, 7:35 PM EDT
Completed Not applicable Interventional

Study of Subtalar Arthrodesis Using AlloStem® Versus Autologous Bone Graft

NCT01413061
View directory record Official record
Conditions
Degenerative Osteoarthritis, Post-traumatic; Arthrosis, Rheumatoid Arthritis & Other Inflammatory Polyarthropathies, Rheumatoid Arthritis of Subtalar Joint
Interventions
Subtalar Arthrodesis
Procedure
Lead sponsor
AlloSource
Industry
Eligibility
18 Years to 80 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
5
States / cities
Baltimore, Maryland • Grand Rapids, Michigan • Edina, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Sep 6, 2026, 7:35 PM EDT
Completed Phase 2 Interventional Results available

Therapeutic Use of Intravenous Vitamin C in Allogeneic Stem Cell Transplant Recipients

NCT03613727
View directory record Official record
Conditions
Lymphoid Leukemia, Myeloid Leukemia, Monocytic Leukemia, Myelodysplasia
Interventions
Intravenous (IV) and oral Vitamin C
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 77 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 6, 2023 · Synced Sep 6, 2026, 7:35 PM EDT
Not yet recruiting Phase 2 Interventional

Naive T Cell Deplete Grafts for GVHD Prevention in Non-Malignant Diseases

NCT07660783
View directory record Official record
Conditions
Bone Marrow Failure, Hemoglobinopathies, Primary Immune Deficiency (PID), Autoimmune Cytopenia, Immune Dysregulation, Hemophagocytic Lymphohistiocytosis (HLH), Non Malignant Disorders
Interventions
ALLOGENEIC CD34+ ENRICHED AND CD45RA- DEPLETED PBSCs
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
6 Months to 50 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 6, 2026, 7:35 PM EDT
Completed Phase 1 Interventional

Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure

NCT00062621
View directory record Official record
Conditions
Kidney Failure, Chronic, Multiple Myeloma
Interventions
Combined bone marrow and kidney transplant
Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Sep 6, 2026, 7:35 PM EDT
Completed Phase 2 Interventional Results available

Cellular Therapy With Cord Blood Cells

NCT00427557
View directory record Official record
Conditions
Multiple Myeloma, Leukemia, Lymphoma
Interventions
Fludarabine, Melphalan, Umbilical Cord Blood, Rituximab, Peripheral Blood Stem Cell Infusion
Drug · Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 80 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 27, 2012 · Synced Sep 6, 2026, 7:35 PM EDT
Active, not recruiting Phase 2 Interventional

Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant

NCT03924401
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
Abatacept
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 20 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
9
States / cities
Birmingham, Alabama • Wilmington, Delaware • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 6, 2026, 7:35 PM EDT
Completed Not applicable Interventional Results available

Ridge Preservation After Tooth Extraction Using Cortical Versus Cancellous Freeze Dried Bone Allograft

NCT01588444
View directory record Official record
Conditions
Tooth Extraction
Interventions
cortical FDBA, Cancellous FDBA
Device
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
19 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 21, 2015 · Synced Sep 6, 2026, 7:35 PM EDT
Terminated Phase 2 Interventional Results available

Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)

NCT01518153
View directory record Official record
Conditions
Leukemia, Lymphoma, Myeloma, Myeloproliferative Diseases
Interventions
Fludarabine, Melphalan, Alemtuzumab, Stem Cell Infusion, Tacrolimus, Methotrexate, G-CSF, Low Dose Donor T-Cells, High Dose Donor T-Cells
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 16, 2016 · Synced Sep 6, 2026, 7:35 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

NCT05088356
View directory record Official record
Conditions
Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Interventions
Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan, CliniMACS CD34 Reagent System, Tacrolimus, Cyclophosphamide, Plerixafor, Filgrastim granulocyte colony-stimulating factor (G-CSF) or equivalent, Thiotepa, Mycophenolate Mofetil (MMF), Ruxolitinib, Sirolimus
Drug · Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 75 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Sep 6, 2026, 7:35 PM EDT
Completed Phase 2 Interventional

Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults

NCT00001637
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Graft vs Host Disease, Leukemia, Myelodysplastic Syndrome, Myeloid Leukemia
Interventions
Blood cell transplantation
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
55 Years to 71 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Sep 6, 2026, 7:35 PM EDT